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Abstract
Background: This study was designed to investigate cognitive abilities and their correlations with
CTG repeat expansion size in classical Myotonic dystrophy type 1 (DM1), given that earlier studies
have indicated cognitive deficits, possibly correlating with blood CTG repeats expansion size.
Methods:  A measurement of CTG repeat expansion in lymphocytes and an extensive
neuropsychological examination was made in 47 patients (25 women and 22 men). Individual results
in the examination were compared with normative data.
Results: A substantial proportion of patients with DM1 (> 40%) scored worse in comparison to
normative collectives on tests measuring executive, arithmetic, attention, speed and visuospatial
abilities. We found significant correlations between longer CTG repeat expansion size and lower
results on most tests associated with these abilities. Furthermore, the association between
executive (frontal) deficits and DM1 were strengthened when considering both test results and
correlations with CTG repeat expansion size in lymphocytes.
Conclusion: This study showed deficits in several cognitive abilities when patients with DM1 are
compared to normative collectives. Some of the neuropsychological tests associated with these
abilities are correlated to CTG repeat expansion size in blood. These data highlight the importance
of considering cognitive deficits when seeing patients with classical DM1 in clinical practice, but also
the utility of using blood CTG repeat expansion size as a broad predictor of finding cognitive deficit
in DM1.
Background
Myotonic dystrophy type 1 (DM1) is the most common
neuromuscular disorder with a debut in adult age. This
progressive autosomal dominant multisystem disease is
characterized by a variable clinical presentation, including
ocular, neuromuscular, endocrine, cardiovascular, gas-
trointestinal and neurological abnormalities [1]. DM1 is
categorized in four groups depending on age of onset and
disease severity; the present paper concerns classical DM1,
in which symptoms presents during the second decade or
later [2]. The molecular basis has been identified in an
unstable (CTG)n repeat located in the 3' untranslated
region of the myotonin protein kinase (DMPK) gene on
chromosome 19 [3]. CTG-repeat number ranges between
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5 and 37 in the normal population, while in DM1 it
exceeds 50, and can even increase to several thousand
units [4]. How an expansion in a non-coding region of the
gene cause the multisystemic features of the disease is
debated, but the most reliable hypothesis postulates that
the abnormal expansion in the DMPK gene causes a repeat
expansion expressed at the RNA level, altering RNA
processing, at least in part by interfering with alternative
splicing of other genes [4].
As summarized by Ashizawa [5] pathology has been iden-
tified in the central nervous system, including cell loss,
atrophy, focal white matter lesions and reduced cerebral
blood flow in various cortical and subcortical areas of the
brain. The frontal and parietal lobes are particularly
affected [6]. Several neuropsychological studies have
showed reduced IQ-levels in concert with deficits in exec-
utive function and visuospatial construction ability [7,8].
Abnormal scores on measures of visual or verbal memory
have been reported by some authors [9] but not by others
[10]. Mixed results have been found regarding verbal abil-
ity, speed and attention [6]. DM1 has also been associated
with emotional- and personality disorder [11,12].
While disease severity and age of onset correlate with
number of CTG repeats in lymphocytes [13] the associa-
tion between cognition and CTG repeat number is more
elusive. As shown in Table 1 several studies have identi-
fied correlations between cognitive ability (most promi-
nently IQ measures) and CTG repeat expansion size, but
later investigations have not confirmed these results. Dis-
crepancies may be explained by methodological differ-
ences and by features of the examined patient group,
including group-size and patient category. However,
taken together evidence exist to conclude that blood CTG
repeat expansion size correlates with cognition, especially
when considering the entire DM1 spectrum, which ranges
from mental retardation (congenital DM1) to subtle
memory deficits (minimal DM1) [14,9]. In order to fur-
ther explore the association we investigated 47 patients
with classical DM1, using a comprehensive neuropsycho-
logical examination, and correlated test results with CTG
repeat expansion size in blood lymphocytes.
Methods
Participants
Patients with DM1 were recruited from the Neuromuscu-
lar Center at the Sahlgrenska University Hospital, Möl-
ndal, Sweden. Inclusion criteria were: age 18–65 years
with no history of major psychiatric or somatic illness,
acquired brain injury or alcohol misuse. Patients with the
congenital, childhood or mild DM1 were excluded [2].
The diagnosis was confirmed by an expansion of CTG-
repeats. Fifty-nine patients at the clinic, meeting the crite-
ria of classical DM1 were invited to participate. Twelve
declined, leaving 47 (25 women and 22 men, mean age
42 years: age range 23–62 years). Clinical and demo-
graphic background data are presented in Table 2. The
range of CTG triplets repeat expansion was 70–1550. All
participants gave informed consent and the medical ethics
committee at the Sahlgrenska Academy, Göteborg Univer-
sity, approved the study. Clinical data was collected by a
self-rating procedure designed at the Neuromuscular
Center aimed to explore the presence or absence of differ-
ent symptoms. Muscle function was measured by a phys-
iotherapist using Brooke's grading system of mobility
[15]. Furthermore an occupational therapist measured
grip force using the Grippit instrument [16].
Neuropsychological tests
All subjects participated in a neuropsychological investi-
gation comprising the Wechsler Adult Intelligence Scale –
Revised (WAIS-R) [16] and tests measuring verbal fluency:
FAS [18], visual construction and memory ability: Rey
Table 1: Studies investigating the correlation between neuropsychological test scores and CTG repeat expansion size in DM1.
Authors* Number 
of patients
Tests Main conclusion
Turnpenny et al. [34] 55 WAIS (short version). Increase in repeat size associated with lower IQ.
Damian et al. [10] 28 Neuropsychological test battery†. Large repeat size (>1000) associated with cognitive impairment.
Jaspert et al. [33] 14 MMSE, MWT-B, Progressive matrices. Large repeat size (> 1000) associated with cognitive impairment.
Rubinsztein et al. [9] 36 MMSE, NART, Progressive matrices. Mild DM1 associated with impaired memory function.
Perini et al. [25] 17 WAIS CTG correlates with total IQ and non-verbal IQ.
Marchini et al. [13] 24 WAIS CTG correlates with all IQ measures and short-term memory (Digit 
span).
Steyaert et al. [14] 24 WISC CTG correlates with IQ in childhood type of DM1.
Meola et al. [8] 19 Neuropsychological test battery.† No correlation between CTG repeat size and test performance.
Modoni et al. [24] 70 Neuropsychological test battery.† No correlation between CTG repeat size and test performance.
* Referred articles are presented in the reference section.
† Batteries including tests aimed to measure a wide variety of neuropsychological functions. WAIS = Wechsler Adult Intelligence Scale; MMSE = 
Mini Mental State Examination; MWT-B = Mehrfach- Wahl-Wortschatz-Test; NART = National Adult Reading Test; WISC = Wechslers Adult 
Intelligence Scale for Children.Behavioral and Brain Functions 2006, 2:16 http://www.behavioralandbrainfunctions.com/content/2/1/16
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Complex Figure Test (RCFT) [19], verbal memory: Rey
Auditory Verbal Learning Test (RAVLT) [20], speed: Trail
Making Test A [21], Stroop Colour Word Test B (CWT B)
[22], attention: Trail Making Test [21] and executive func-
tion: Wisconsin Card Sorting Test (WCST) [23], TMT B
[21] and Stroop Colour Word Test B [22]. The tests were
administered in a quiet room in two sessions of approxi-
mately two hours each. Following recommendations by
Mitrushina et al. [22] individual performance was com-
pared to age-normative data (see reference for respective
test above).
Genetic analysis
DNA was extracted from peripheral blood lymphocytes
and analysed for expansion of the CTG-repeat in the
DMPK gene. The analysis was performed with PCR and
southern blot using the probe pM10M6 [3]. The size of
CTG-expansion was assessed visually from exposed x-ray
films. As most patients with DM1 show a smear rather
than a distinct band, because of somatic mosaicism, the
approximate midpoint of the smear was reported.
Statistical analysis
Data were analysed using SPSS base 11.5 (Chicago, IL)
and are presented as median and interquartile range
except from demographic and clinical data. The Spearman
rank correlation test was used to analyse correlations
between CTG repeat number and scores on separate neu-
ropsychological tests. The significance level was set at 0.05
for all parameters.
Results
The results of test performance and correlations with
CTG-repeat expansion are presented in Table 3. Mean
total IQ (WAIS-R) was 95. As compared to normative
data, and using 1 SD below normative mean as a sign of
impairment, patients with DM1 scored worse on a major-
ity of tests (in the normative collectives 16 % of subjects
are expected to perform 1 SD below mean). More than 40
% of the patients scored 1 SD < normative mean on tests
associated with executive function (WCST, TMT B, CWT
B), speed (TMT, Digit symbol, CWT B), attention (Digit
span, Digit symbol, TMT), visuospatial- (RCFT, Object
assembly, Block design) and arithmetic ability (Arithme-
tic). Furthermore, patients with DM1 scored worse than
normative samples on RAVLT (immediate recall), Picture
Arrangement, RCFT (delayed recall), Vocabulary and Sim-
ilarities. On average, DM1 patients scored 1 SD below the
mean on 7 of 20 tests (median = 7, range = 0 -18) in the
examination. Most constituent tests (except from WCST
and RAVLT) correlated positively with one another. No
combination of aberrant tests (defined as 1 SD < norma-
tive mean) was found to be typical for the group of DM1
patients. Rather the pattern of combinations was hetero-
geneous. To explore if any of the tests in the data set could
predict total number of test failed we investigated the cor-
relation between results on each individual test and the
total number of tests failed. We found significant correla-
tions between a majority of tests (mean Rho = -0.539) and
the total number of failed tests for each patient, indicating
that no test had unique predictive value. Significant nega-
tive correlations with CTG-repeat expansion size were
found on tests associated with executive function (WCST,
CWT B and TMT B), arithmetic (Arithmetic), visuospatial
construction (RCFT, copy trial), speed and attention
(TMT) and verbal ability (Vocabulary and Comprehen-
sion). In addition, as illustrated in Figure 1, the number of
CTG triplets correlated with global cognitive impairment
(i.e. number of tests with results 1 SD < normative mean).
Patients reporting subjective problems with fatigue, hear-
ing and/or vision were undistinguishable from the
patients without such problems, as assessed with the Wil-
coxon rank sign test. There were no gender differences in
the performance on the neuropsychological tests in the
DM1 group.
Discussion
This study showed a significant negative correlation
between CTG repeat expansion size and scores on tests
depending on executive, arithmetic, attention, visuospa-
tial, speed and verbal ability. This means that poorer per-
formance on these tests is associated with longer CTG-
repeats as measured in blood lymphocytes (indicating an
association with repeat size). Furthermore, a substantial
proportion of DM1 patients scored worse on tests associ-
ated with these abilities (verbal ability excluded). Differ-
ences in neuropsychological performance between
patients with classical DM1 and controls have been
shown in earlier studies on tests measuring speed and
Table 2: Demographic and clinical description of DM1 patients
Variable DM1 (n = 47)
Age (years) 41.55 (10.4)
Gender 22 M, 25 F
Age at onset* 27.6 (11.0, 12–50)
Education (years) 10.8 (2.1)
Married/cohabiting 60 %
Hearing impairment 28%
Vision impairment 49%
Fatigue 79 %
Day-time sleepiness 66 %
Reduced initiative 43 %
Brooke-rating** 0.51 (1.1, 0–5)
Grip force† (N) 97.5 (48.5)
* Results are presented in mean (sd, range).
** Brooke's functional test and grading system measuring mobility 
(hips and legs). In the grading system, zero implies normal function 
and higher values indicates increasing levels of immobility.
† Measurement of grip force using the Grippit instrument. Mean (sd) 
for healthy controls = 331 (77) [16].Behavioral and Brain Functions 2006, 2:16 http://www.behavioralandbrainfunctions.com/content/2/1/16
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attention [25], executive [8], visuospatial [7] and arithme-
tic ability [25]. Our study not only confirms these results
but also show significant correlations between poorer
results on certain tests associated with these abilities and
larger CTG repeat expansion size as measured in blood.
Note, however, that certain tests associated with speed
and attention (Digit span, Digit symbol) and visuospatial
construction ability (Block design and Object assembly)
are not correlated with CTG expansion size, making this
association more uncertain. Furthermore, poor test per-
formance, as defined here, indicates that the result is in
the borderline-range and not necessarily associated with
severe cognitive impairment [22]. However, results on
TMT B seem particularly problematic for DM1 patients, in
that 64 % of the patients score 2 SD < mean (indicating
severe impairment). Besides being an indicator of execu-
tive dysfunction, TMT B is associated with several cogni-
tive functions and, correspondingly, diffuse brain damage
[21].
Two forms of intelligence have been distinguished: fluid
intelligence (FI) (abilities to acquire new concepts and to
adapt to unfamiliar situations) and crystallized intelli-
gence (CI) (a system of well-learned intellectual skills or
knowledge accumulated over a lifetime) [26]. The acqui-
sition of knowledge (CI) depends on well-functioning
attention, speed and problem-solving ability (FI). When
reviewing the cognitive profile in DM1 a picture emerges
that connects to these aspects of intelligence. Results
broadly indicate performance in the normal range on tests
associated with CI (verbal subtests/semantic knowledge
in WAIS-R) and below the normal range on tests measur-
ing FI (nonverbal subtests in WAIS-R and tests depending
on speed and executive ability). Given that CI depends
upon the integrity of FI, one might infer that FI-related
dysfunctions arise late in classical DM1; early deficits
would be expected to manifest themselves as deficits also
in CI. The FI-CI pattern in DM1 also broadly resembles
the cognitive profile associated with aging [27]. In this
context, it is interesting to note that DM1 has been termed
a progeroid (early aging) syndrome [28], with a prema-
ture decline of age somatic/brain functions [5]. However,
cognitive decline have been reported by some authors
[29] but not by others [30]. Taking the progeroid nature
of DM1 into account, it is reasonable to perform further
longitudinal studies on cognition in classical DM1.
The presence of somatic mosaicism in the tissues of
patients with DM1 has been noted in earlier studies [31]
and challenges the assumption that CTG repeat expansion
as measured in blood lymphocytes correspond to CTG
repeat expansion in brain (and indirectly cognition). Ser-
geant et al. [32] have documented the presence of very
large CTG expansions in brain tissue of DM1 patients
characterized by much smaller size of CTG in lym-
phocytes. These authors also documented mosaicism in
different brain areas. Modoni et al. [24] used mosaicicm
to explain the absence of correlation between blood CTG
repeats and neuropsychological test performance. Our
data did reveal a significant correlation between blood
CTG and certain aspects of cognition and this suggests at
least some value of using CTG repeat expansion size in
lymphocytes as a broad predictor of cognitive impairment
in DM1. This estimate should however be used with cau-
tion when considering the heterogeneity that actually
appear when examining the number of cognitive deficits
shown by patients with similar CTG-repeat expansion
sizes (Figure 1).
The significance of other impairments, such as reduced
eyesight and daytime fatigue, on neuropsychological
functioning is uncertain [33]. One drawback of our and
other studies, as summarized in Ashizawa [5] and
D'Angelo and Bresolin [6], is that they do not assess these
features in sufficient detail to permit evaluation of their
significance. When considering CTG repeat expansion as
measured in blood, one might speculate that this measure
at the most indicates a general disease process, due to the
fact that CTG-repeat expansion affect different bodily tis-
sues [13]. If true, the correlation between CTG repeat size
and cognition may not only be influenced by brain-
Correlation between CTG repeats expansion size and total  number of tests 1 SD < normative mean Figure 1
Correlation between CTG repeats expansion size 
and total number of tests 1 SD < normative mean. 
Correlation between CTG repeats expansion size and total 
number of tests 1 SD < normative mean in patients with 
DM1 (P = < 0.05, rho = 0.30).Behavioral and Brain Functions 2006, 2:16 http://www.behavioralandbrainfunctions.com/content/2/1/16
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related pathology [10] but also by fatigue, poor eyesight
and manual weakness. These potential predictors should
be explored in future studies on the cause of cognitive def-
icits in DM1.
Conclusion
This study show deficits in tests associated with executive,
visuospatial, arithmetic, attention and speed dependent
ability when patients with DM1 are compared to norma-
tive collectives. Some of the neuropsychological tests asso-
ciated with these abilities are correlated to CTG repeat
expansion size in blood. These data highlight the impor-
tance of considering cognitive deficits when seeing
patients with classical DM1 in clinical practice, but also
the utility of using blood CTG repeat expansion size as a
broad predictor of finding cognitive deficit in classical
DM1.
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